<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622617</url>
  </required_header>
  <id_info>
    <org_study_id>NEUROTOX</org_study_id>
    <nct_id>NCT05622617</nct_id>
  </id_info>
  <brief_title>Relationship Between Serum Interleukin-20 Level and Paclitaxel-associated Neuropathy</brief_title>
  <acronym>NEUROTOX</acronym>
  <official_title>Prospective Observational Investigation of Serum Interleukin-20 Level and Paclitaxel-Associated Neuropathy in Breast Cancer Patients Receiving Paclitaxel Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namik Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Namik Kemal University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the correlation between paclitaxel-induced neuropathy and the&#xD;
      measurement values of serum IL-20 levels at baseline and during chemotherapy in patients who&#xD;
      will receive neoadjuvant or adjuvant paclitaxel chemotherapy with the diagnosis of&#xD;
      early-stage or locally advanced breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients with the diagnosis of breast cancer who will be started on adjuvant or&#xD;
           neoadjuvant paclitaxel chemotherapy will be included in the study.&#xD;
&#xD;
        -  Patients who will receive standard breast cancer treatment (4 cycles of cyclophosphamide&#xD;
           600mg/m2 every 21 days + epirubicin 90mg/m2 followed by weekly paclitaxel 80 mg/m2 x 12&#xD;
           sessions) will be included in the study.&#xD;
&#xD;
        -  Age, gender, additional disease, diagnosis dates, previous diseases and breast cancer&#xD;
           subtypes of the patients who signed the informed consent form will be obtained from the&#xD;
           electronic information system or by asking face-to-face.&#xD;
&#xD;
        -  Serum IL-20 level will be studied from blood tests taken for routine chemotherapy. no&#xD;
           extra blood sample will be taken for the study&#xD;
&#xD;
        -  Neuropathy assessment will be evaluated with Organisation for Research and Treatment of&#xD;
           Cancer (EORTC) chemotherapy-induced peripheral neuropathy (QLQ-CIPN20) Questionnaire,&#xD;
           the sensitivity, and specificity of which have previously been demonstrated for&#xD;
           chemotherapy-induced neuropathy. The Turkish validation questionnaire of the study,&#xD;
           which was made before, will be conducted by the physician in charge before the&#xD;
           paclitaxel chemotherapy and at the 1st and 12th weeks after the treatment, by asking the&#xD;
           patient face to face.&#xD;
&#xD;
        -  patients with diabetes mellitus and patients who had a history of peripheral neuropathy&#xD;
           will be excluded from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship with paclitaxel associated neuropathy and serum IL-20 level</measure>
    <time_frame>January 01,2022 -December 31, 2022 is the deadline for patient inclusion</time_frame>
    <description>Neuropathy measurement will be made face-to-face by the attending physician with a European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-induced peripheral neuropathy (CIPN) Questionnaire after the first week after paclitaxel chemotherapy and the last week of 12 cycles of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship with paclitaxel associated neuropathy and serum IL-20 level</measure>
    <time_frame>December 31, 2022 is the deadline for patient inclusion</time_frame>
    <description>Neuropathy measurement will be made face-to-face by the attending physician with a European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-induced peripheral neuropathy (CIPN) Questionnaire after the first week after paclitaxel chemotherapy and the last week of 12 cycles of treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuropathy Associated With Dysproteinaemias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving standard breast cancer treatment containing taxane&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients receiving paclitaxel chemotherapy for local advanced or early-stage breast&#xD;
             cancer&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  advanced stage breast cancer&#xD;
&#xD;
          -  having before peripheral neuropathy&#xD;
&#xD;
          -  patients with diabetes mellitus&#xD;
&#xD;
          -  &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only the female gender will be enrolled</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>kubilay karaboyun, m.d.</last_name>
    <phone>+90 0554 2916110</phone>
    <email>kubilaykaraboyun@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tekirdag Namik Kemal University</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kubilay Karaboyun, m.d.</last_name>
      <phone>+90 0 5542916110</phone>
      <email>kubilaykaraboyun@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Namik Kemal University</investigator_affiliation>
    <investigator_full_name>Asoc. Prof. Erdoğan Selçuk Şeber</investigator_full_name>
    <investigator_title>Asoc Prof.</investigator_title>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>Peripheral Neuropathy Induced by Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

